Create Account | Sign In: Author or Forum

Search Symptoms

Category: Endocrinology | Ophthalmology | Pathology | Journal

Back to Journal Articles

Cell Abnormality Linked to Diabetic Retinopathy

Last Updated: February 17, 2012.

Type 1 diabetes patients with early retinopathy have abnormalities in their endothelial progenitor cells, a cell type released into the circulation as a result of vascular damage, according to a study published online Feb. 14 in Diabetes.

FRIDAY, Feb. 17 (HealthDay News) -- Type 1 diabetes patients with early retinopathy have abnormalities in their endothelial progenitor cells (EPC), a cell type released into the circulation as a result of vascular damage, according to a study published online Feb. 14 in Diabetes.

Gianpaolo Zerbini, M.D., Ph.D., from the San Raffaele Scientific Institute in Milan, and colleagues investigated whether EPC could be used as a biomarker of early nonproliferative diabetic retinopathy in 20 type 1 diabetes patients 20 years or younger with retinopathy, 19 type 1 diabetes patients 7 years or younger without retinopathy, and 17 type 1 diabetes patients 23 years or older without retinopathy. Each group also had a similar number of matched controls without diabetes.

The researchers found that, of the two subtypes of EPC, only the form carrying both endothelial and monocytic markers known as colony-forming units (CFU)-Hill cells was associated with retinopathy. EPC from patients with retinopathy formed more colonies in vitro and had reduced levels of proteins involved in homing at sites of vascular injury.

"CFU-Hill cells are potential informers of diabetic microangiopathy but may be preempted from carrying out reparative functions if the molecular abnormalities compromise interactions with the damaged vascular wall," Zerbini and colleagues conclude.

Abstract
Full Text (subscription or payment may be required)


Previous: Improved Availability of Sunscreen Increases Usage Next: Pregnancy Complications Tied to CVD Later in Life

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion: